Neoplasms, Plasma Cell: all 2,314 studies
Page 1 of 24. Open to participants first (247), then studies with results posted, then the rest; newest registration first within each.
- A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard TreatmentsNot yet recruitingNCT07881835Phase 4
- Immunoprofiling of the Patient Tumor Microenvironment in BCMA Targeted TherapiesNot yet recruitingNCT07878208
- Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)Not yet recruitingNCT07831122Phase 1
- Real-life Study on the Use of Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Relapsed/Refractory Multiple MyelomaRecruitingNCT07777406
- BCMA/GPRC5D Trispecific Antibody Treatment for Newly Diagnosed Amyloidosis (AL-004)Not yet recruitingNCT07751471Phase 2
- Rutgers University Study of the Genetics of Blood CancersRecruitingNCT07714044
- Delayed Toxicities Post-CAR-TRecruitingNCT07665307
- Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness LevelRecruitingNCT07649525Phase 3
- Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple MyelomaNot yet recruitingNCT07600151Phase 1/2
- In Vivo BCMA/GPRC5D Tandem Dual CAR-T Therapy for Relapsed/Refractory Plasma Cell NeoplasmsRecruitingNCT07586709Early Phase 1
- REal World MAIA UK OutcomEsNot yet recruitingNCT07532473
- Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT07529782Phase 1
- CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell NeoplasmsRecruitingNCT07519187Early Phase 1
- Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic MalignancyRecruitingNCT07426484Phase 4
- AI-Based Fine Morphological Subtyping of Myeloma Single Cells for Predicting FISH AbnormalitiesEnrolling by invitationNCT07410403
- Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell ImmunotherapyRecruitingNCT07390071Not applicable
- Multiple Myeloma Extramedulary Disease Samples FFPENot yet recruitingNCT07354555
- 68Ga-BCMA PET/CT in Multiple MyelomaRecruitingNCT07319897Phase 2/3
- Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)RecruitingNCT07202091Phase 2/3
- Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)RecruitingNCT07202078Phase 2/3
- Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)RecruitingNCT07202065Phase 2/3
- Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)RecruitingNCT07202052Phase 2/3
- A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple MyelomaRecruitingNCT07106671Phase 2
- CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell NeoplasmsNot yet recruitingNCT07077330Early Phase 1
- Subcutaneous Daratumumab Administration in the Thigh Vs Abdomen in Plasma Cell DisordersRecruitingNCT07075510Phase 1/2
- A Music Therapy Study for Blood Cancer Survivors With Cognitive DifficultiesRecruitingNCT07052916Not applicable
- Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple MyelomaRecruitingNCT07032129Phase 1/2
- A Study on the Use of Sulpegfilgrastim to Prevent the Incidence of Neutropenia With Infection in Newly Diagnosed Non-transplant Multiple Myeloma PatientsNot yet recruitingNCT07018271Not applicable
- CAR19BCMA CAR-T Cells for the Treatment of R/R Plasma Cell Neoplasms and Lymphomas/Leukemias With Plasmacytic DifferentiationNot yet recruitingNCT06986434Early Phase 1
- Evaluation of Skin Tests in Biotherapy AllergiesRecruitingNCT06971848Not applicable
- Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain AmyloidosisRecruitingNCT06971380Phase 2
- Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCTNot yet recruitingNCT06963866Phase 2
- Intravenous Autologous CD19 CAR-T Cells for R/ R MM, B-ALL, and B-Cell LymphomaRecruitingNCT06961669Not applicable
- Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed MyelomaRecruitingNCT06947083Phase 2
- Comparison of Elranatamab and Lenalidomide Versus Daratumumab and Lenalidomide as Post-transplant Maintenance Therapy in Patients With Newly Diagnosed Myeloma (ElMMA)Not yet recruitingNCT06931704Phase 2
- A Clinical Trial Evaluating the Safety Tolerability, Radiation Absorption Dose, Distribution, PET Imaging and Histological Expression of 68Ga-NOTA-SCH001 in Patients With Multiple MyelomaNot yet recruitingNCT06925958Not applicable
- CAR-T Cell Therapy Combined With Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory Multiple MyelomaNot yet recruitingNCT06913179Phase 1
- The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic TumorsRecruitingNCT06911710Phase 1/2
- A Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple MyelomaNot yet recruitingNCT06895512Phase 3
- Whole Body MRI in OncologyRecruitingNCT06895291
- Multiple Myeloma is a Hematologic Malignancy Characterized by the Accumulation of Malignant Plasma Cells in the Bone Marrow. Despite Advances in Treatment, Many Patients Experience Disease Relapse. Bispecific Antibodies Offer an Innovative Therapeutic Approach, But Approximately 30%-40% of PatientsNot yet recruitingNCT06888856
- LCAR-M61SQ in Treatment of Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT06888752Not applicable
- Teclistamab Plus Autologous Lymphocyte Infusion (ALI) for the Treatment of R/R Multiple MyelomaNot yet recruitingNCT06880601Phase 2
- KPD Consolidation After ASCT in NDMM PatientsRecruitingNCT06879379Phase 2/3
- Pre-malignant States to Hematologic Malignancies in FirefightersRecruitingNCT06870760
- Cost-utility Analysis of Ambulatory Dose Escalation of Bispecific Antibodies in Multiple Myeloma.RecruitingNCT06846905
- Developing a Patient-Reported Outcome (PRO) Screening Measure for Infections and Measuring Quality of Life in Hematological Patients With Secondary Immunodeficiency (SID) Across the Treatment Trajectory - The PRO SID ProjectRecruitingNCT06821880
- Development of an Intervention Integrating Procedures Combining Hypnosis and Virtual Reality in the Support of Patients with Hematological CancerNot yet recruitingNCT06817759Not applicable
- A Phase Ib/II Clinical Study on the Application of Linperlisib Combined with the VRD Regimen in Newly Diagnosed Patients with Multiple MyelomaNot yet recruitingNCT06799676Phase 1/2
- A Study of ESO-T01 in Treating Relapsed/ Refractory Multiple MyelomaRecruitingNCT06791681Early Phase 1
- A Machine Learning Approach to Connect Multiple Myeloma Complexity to Early Disease RecurrenceRecruitingNCT06767254
- Longitudinal Data Registry of Plasma Cell DyscrasiaRecruitingNCT06760052
- Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)RecruitingNCT06759181Phase 1/2
- Low Dose Teclistamab in Newly Diagnosed Multiple Myeloma PatientsRecruitingNCT06758375Phase 2
- Multi-center Screening for Serum M ProteinNot yet recruitingNCT06750965
- SIL as Maintenance Therapy in Multiple MyelomaNot yet recruitingNCT06744894Phase 2
- To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple MyelomaNot yet recruitingNCT06742138Phase 3
- A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple MyelomaRecruitingNCT06732232Early Phase 1
- a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell LeukemiaRecruitingNCT06718270Early Phase 1
- A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple MyelomaRecruitingNCT06717113Early Phase 1
- Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple MyelomaNot yet recruitingNCT06705725Phase 1
- A Clinical Study of TQB2029 for Injection in Subjects With Multiple MyelomaRecruitingNCT06700395Phase 1
- Risk Stratification and MRD-driven Maintenance for MM After ASCTRecruitingNCT06697483Not applicable
- Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) PatientsRecruitingNCT06682156
- An Open-Label Clinical Study of the Efficacy and Safety of BCD-248 in Patients with Relapsed/Refractory Multiple MyelomaRecruitingNCT06668792Phase 2
- 5p15/ 9q22/ 15q22 Hyperdiploidy and Their Significance in Multiple Myeloma PatientsNot yet recruitingNCT06667583
- A Real-World Observational Study: Zevorcabtagene Autoleucel Injection in Patients with Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT06659770
- Comparison Between Whole Body DWI and FDG PET/CT in Patients with Simptomatic Multiple MyelomaRecruitingNCT06659276
- An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell LeukemiaNot yet recruitingNCT06655519Phase 1
- BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple MyelomaRecruitingNCT06644443Phase 1/2
- A Study of OL-101 Injection in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)RecruitingNCT06644118Phase 1
- Allogeneic Anti-BCMA/GPRC5D Bispecific CAR-NK Cells (ACT-001) in Patients With Relapsed or Refractorymultiple MyelomaNot yet recruitingNCT06594211Not applicable
- Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple MyelomaRecruitingNCT06581640Phase 2
- Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple MyelomaRecruitingNCT06574126Phase 2
- Study Comparing Therapy for Advanced Relapsed/Refractory Multiple Myeloma With and Without DexamethasoneRecruitingNCT06561854Phase 3
- DAratumumab and REvlimid REfractory MMRecruitingNCT06541860
- Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma PatientsRecruitingNCT06520176Phase 3
- Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMMRecruitingNCT06518551Phase 1/2
- Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MMRecruitingNCT06515262Not applicable
- Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma PatientsRecruitingNCT06505369Phase 2
- Nanobody-based Biepitope CAR-T Cells Targeting BCMA in the Treatment of R/RMMRecruitingNCT06503107Phase 1/2
- A Study of QLS4131 in Patients With Recurrent or Refractory Multiple MyelomaNot yet recruitingNCT06500507Phase 1
- HEME Home Transfusion ProgramRecruitingNCT06487247Not applicable
- Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaRecruitingNCT06484829Phase 1/2
- Bleeding in Multiple MyelomaNot yet recruitingNCT06482931
- LCAR-M61S and LCAR-M61D in Treatment of Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT06472479Not applicable
- Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or NotRecruitingNCT06463717
- Clinical Outcomes and Prognostic Factors in Multiple Myeloma PatientsNot yet recruitingNCT06457464
- Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease DetectionRecruitingNCT06409702Phase 4
- Study of CT071 Injection in High Risk Newly Diagnosed Multiple MyelomaRecruitingNCT06407947Early Phase 1
- A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.Not yet recruitingNCT06369935
- Study of SYS6020 in BCMA-positive Multiple MyelomaNot yet recruitingNCT06359509Early Phase 1
- Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCLNot yet recruitingNCT06333509Phase 1/2
- Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for TransplantationRecruitingNCT06324266Phase 2/3
- Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone DiseaseNot yet recruitingNCT06314698Phase 3
- High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell DisordersRecruitingNCT06313502Phase 1
- Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple MyelomaRecruitingNCT06302699
- To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT06298266Early Phase 1
- A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple MyelomaRecruitingNCT06296121Phase 3
- Comparison of the Complications in Multiple Myeloma Patients Who Received Autologous Stem Cell Transplantation Between in HEPA-filtered Room and Non-HEPA-filtered RoomNot yet recruitingNCT06286241